z-logo
open-access-imgOpen Access
Ribosome assembly factor URB1 contributes to colorectal cancer proliferation through transcriptional activation of ATF4
Author(s) -
Wang Tao,
Li LaiYuan,
Chen YiFeng,
Fu SiWu,
Wu ZhiWei,
Du BinBin,
Yang XiongFei,
Zhang WeiSheng,
Hao XiangYong,
Guo TianKang
Publication year - 2021
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14643
Subject(s) - atf4 , gene silencing , cancer research , biology , xbp1 , transcription factor , carcinogenesis , microbiology and biotechnology , cancer , rna , genetics , gene , rna splicing
Ribosome assembly factor URB1 is essential for ribosome biogenesis. However, its latent role in cancer remains unclear. Analysis of The Cancer Genome Atlas database and clinical tissue microarray staining showed that URB1 expression was upregulated in colorectal cancer (CRC) and prominently related to clinicopathological characteristics. Silencing of URB1 hampered human CRC cell proliferation and growth in vitro and in vivo. Microarray screening, ingenuity pathway analysis, and JASPAR assessment indicated that activating transcription factor 4 (ATF4) and X‐box binding protein 1 (XBP1) are potential downstream targets of URB1 and could transcriptionally interact through direct binding. Silencing of URB1 significantly decreased ATF4 and cyclin A2 (CCNA2) expression in vivo and in vitro. Restoration of ATF4 effectively reversed the malignant proliferation phenotype of URB1‐silenced CRC cells. Dual‐luciferase reporter and ChIP assays indicated that XBP1 transcriptionally activated ATF4 by binding with its promoter region. X‐box binding protein 1 colocalized with ATF4 in the nuclei of RKO cells, and ATF4 mRNA expression was positively regulated by XBP1. This study shows that URB1 contributes to oncogenesis and CRC growth through XBP1‐mediated transcriptional activation of ATF4. Therefore, URB1 could be a potential therapeutic target for CRC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here